Loading...
XOSL
AKBM
Market cap447mUSD
Apr 30, Last price  
53.00NOK
1D
6.11%
1Q
-19.45%
IPO
-47.00%
Name

Aker Biomarine ASA

Chart & Performance

D1W1MN
P/E
2.48
P/S
2.25
EPS
2.06
Div Yield, %
84.91%
Shrs. gr., 5y
4.89%
Rev. gr., 5y
-4.17%
Revenues
199m
-40.65%
74,053,65612,189,59525,021,78652,050,55355,287,49484,002,607108,993,261112,299,000105,121,000116,737,000125,540,000154,182,000246,170,000288,588,000262,062,000277,200,000335,300,000199,000,000
Net income
180m
P
00028,916,9740046,593,795-17,258,000805,000-2,055,000-17,768,000-1,022,000-23,750,000-5,463,000-8,008,00010,000,000-9,000,000180,300,000
CFO
12m
-74.26%
00002,513,0675,373,3010-11,134,00018,269,00020,880,00007,894,00012,307,000-51,043,000729,00015,100,00047,400,00012,200,000
Dividend
Sep 09, 202445 NOK/sh
Earnings
Jul 10, 2025

Profile

Aker BioMarine AS develops, produces, and sells krill-derived ingredients for nutraceutical, dietary supplement, and animal feed applications in Norway, the Americas, the Asia Pacific, Europe, the Middle East, and Africa. It operates through two segments, Ingredients and Brands. It provides Superba, a krill-based ingredients for nutraceutical, including phospholipid complex of choline, omega-3s, and antioxidant astaxanthin; QRILL Aqua, a krill-based ingredients for aquaculture; and QRILL Pet, a krill-based ingredients animal feed application. The company also offers LYSOVETA, a delivery platform based on LPC-bound EPA and DHA from krill; and INVI, a hydrolyzed protein isolate for food and beverage applications. In addition, it distributes human health and nutrition products, and natural supplements, as well as provides AION, a circular solution provider that recycles waste and re-use materials. The company was founded in 2006 and is headquartered in Lysaker, Norway. Aker BioMarine ASA is a subsidiary of Aker ASA.
URL
https://www.akerbiomarine.com/
IPO date
Jul 06, 2020
Employees
626
Domiciled in
NO
Incorporated in
NO

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
199,000
-40.65%
335,300
20.96%
277,200
5.78%
Cost of revenue
194,190
313,190
248,900
Unusual Expense (Income)
NOPBT
4,810
22,110
28,300
NOPBT Margin
2.42%
6.59%
10.21%
Operating Taxes
100
(25,000)
2,200
Tax Rate
2.08%
7.77%
NOPAT
4,710
47,110
26,100
Net income
180,300
-2,103.33%
(9,000)
-190.00%
10,000
-224.88%
Dividends
(373,200)
Dividend yield
6.34%
Proceeds from repurchase of equity
200
BB yield
-0.01%
Debt
Debt current
7,200
49,000
47,600
Long-term debt
143,300
353,700
344,200
Deferred revenue
100
Other long-term liabilities
20,000
3,700
(100)
Net debt
135,100
375,100
360,600
Cash flow
Cash from operating activities
12,200
47,400
15,100
CAPEX
(17,400)
(45,900)
(46,100)
Cash from investing activities
379,400
(48,900)
(56,400)
Cash from financing activities
(404,000)
6,700
52,500
FCF
361,710
46,310
(1,449)
Balance
Cash
15,000
27,500
21,000
Long term investments
400
100
10,200
Excess cash
5,450
10,835
17,340
Stockholders' equity
(320,400)
(163,600)
(118,500)
Invested Capital
661,800
926,900
878,500
ROIC
0.59%
5.22%
3.05%
ROCE
1.41%
2.90%
3.70%
EV
Common stock shares outstanding
87,681
87,661
90,000
Price
67.10
45.87%
46.00
20.89%
38.05
-29.93%
Market cap
5,883,390
45.90%
4,032,409
17.75%
3,424,500
-28.00%
EV
6,018,490
4,407,509
3,817,900
EBITDA
48,810
72,310
77,700
EV/EBITDA
123.30
60.95
49.14
Interest
2,500
33,400
20,300
Interest/NOPBT
51.98%
151.06%
71.73%